This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.v.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Andreas Kiesow: Innovator in Tetracycline Antibiotics
Introduction
Andreas Kiesow is a notable inventor based in Halle, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of tetracycline antibiotics. His innovative work focuses on enhancing the effectiveness and longevity of these essential medications.
Latest Patents
Kiesow holds a patent for "Tetracycline complexes with sustained activity." This invention relates to the controlled release of tetracycline antibiotics. Specifically, it involves a complex comprising a tetracycline compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, along with a divalent metal carboxylate. The patent outlines a pharmaceutical preparation that includes this complex, methods for manufacturing it, and its application in treating bacterial infections. The invention aims to maintain antibiotic activity over a prolonged period, making it particularly useful for the therapy and prophylaxis of acute, chronic, or recurrent periodontal diseases.
Career Highlights
Throughout his career, Kiesow has worked with prestigious organizations, including the Fraunhofer Society for the Advancement of Applied Research. His work has contributed to advancements in pharmaceutical sciences and has had a positive impact on public health.
Collaborations
Kiesow has collaborated with notable colleagues such as Karsten Mäder and Sandra Sarembe. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.
Conclusion
Andreas Kiesow's contributions to the field of tetracycline antibiotics exemplify the importance of innovation in healthcare. His work not only enhances the effectiveness of treatments but also addresses critical health challenges.